Durvalumab,Tremelimumab
AstraZeneca,Pfizer,AstraZeneca
['nsclc', 'tremelimumab', 'lung', 'sclc', 'durva']
overall survival remained durable in patients with metastatic non small cell lung cancer when tremelimumab was added to durvalumab plus chemotherapy. #nsclc #esmo22 | 
Home of the journal ONCOLOGY®, CancerNetwork® offers different perspectives on oncology/hematology through review articles, news, podcasts, blogs, and more.